Table 1.
Characteristics of 60 patients with STK11 alterations (VUS excluded) (N = 4,446 patients tested)
| Patient characteristics |
STK11 aberrant N = 60 |
STK11 wild type N = 4386 |
P value univariate |
|---|---|---|---|
| Women (N=2272/4446 or 51.1%) | 20/60 (33.3%) | 2252/4386 (51.3%) | 0.006 (Fisher’s Exact test) |
| Median age at diagnosis (range) (years) | 65 (30-87) | 63 (23-92) | 0.3 |
| Median (95% CI) number of tissue co-alterations (not including STK11 or VUS) tissue | 4 (3-5) | 4 (3-5) | 0.6 |
| Median (95% CI) number of ctDNA co-alterations (not including STK11 or VUS) | 4 (3-5) | 4 (3-5) | 0.7 |
| Median overall survival (95% CI) from diagnosis (months) (Kaplan Meier) | 20.5 (17.4-23.5) | 29.1 (26.9-31.3) | 0.03 |
| Median overall survival (95% CI) from diagnosis (months) (Kaplan Meier) in patients with NSCLC (N=384) | 20.5 months (14.7-26.1) N = 27 |
16.9 months (16.7-17.1) N = 357 |
0.1 |
| Median overall survival (95% CI) from diagnosis (months) (Kaplan Meier) in patients with cancers other than non-small cell lung cancer (N=4062) | 20 months (16.9-23.4) N= 33 |
34 months (31-37.1) N=4029 |
0.09 |
| **Median time to progression from date of diagnosis (months) in all patients (N= 4446) | 6.4 months (5.1-7.9) N=60 |
12 months (11.7-12.3) N=4386 |
0.001 |
| **Median time to progression from date of diagnosis (months) in patients with NSCLC (N= 384) | 6.2 months (4.8-7.6) N = 27 |
8.2 months (8-8.4) N = 357 |
0.6 |
| Median time to progression from date of diagnosis of KRAS-mutated all cancers (N=661) | 3.4 months (1.6-5.4) N=27 |
5.6 months (5.3-5.9) N=634 |
0.2 |
| Median time to progression from date of diagnosis of KRAS-mutated cancers other than NSCLC (N=587) | 3.3 months (3.1-3.6) N=11 |
5.5 months (5.2-5.8) N=576 |
0.07 |
| Median time to progression from date of diagnosis of KRAS-mutated NSCLC (N=74) | 3.4 months (0-7.7) N=16 |
6.8 months (6.2-7.4) N=58 |
0.5 |
| Median time to progression from date of diagnosis of KRAS-mutated cancers excluding patients on immunotherapy (N=627) | 3.3 months (3.1-3.4) N=21 |
5.6 months (5.3-5.9) N=606 |
0.4 |
| Median time to progression from date of diagnosis of KRAS-mutated cancers other than NSCLC excluding patients on immunotherapy (N=565) | 3.2 months (1.7-4.7) N=8 |
5.4months (5.2-5.6) N=557 |
0.08 |
| Median time to progression from date of diagnosis of KRAS-mutated NSCLC excluding patients on immunotherapy (N=62) | 3.4 months (0-6.9) N=13 |
6.8 months (6.3-7.3) N=49 |
0.9 |
| Median overall survival (95% CI) from diagnosis (months) (Kaplan Meier) in patients with KRAS mutated NSCLC (N=74) | 20.5 months (8-32.9) N=16 |
16.8 months (15.8-17.8) N=58 |
0.9 |
| Median overall survival (95% CI) from diagnosis (months) (Kaplan Meier) in patients with KRAS mutated cancers other than NSCLC (N=585) | 16.2 months (13-19.6) N=14 |
13 months (12.5-13.5) N= 571 |
0.9 |
| Median overall survival from date of diagnosis of KRAS-mutated cancers excluding patients on immunotherapy (N=627) | 16.2 months (10-22.4) N= 21 |
13.1 months (12.4-13.5) N=606 |
0.4 |
| Median overall survival from date of diagnosis of KRAS-mutated cancers other than NSCLC excluding patients on immunotherapy (N=565) | 13.1 months (0-27) N=8 |
12.7 months (12.4-13.1) N= 557 |
0.9 |
| Median overall survival from date of diagnosis of KRAS-mutated NSCLC excluding patients on immunotherapy (N=62) | 21.3 months (6-36.6) N=13 |
16.6 months (15.8-17.3) N=49 |
0.1 |
| Type of cancer | Cancers tested for STK11 (tissue and/or ctDNA NGS) (N) |
STK11 alterations N (% of cancers) |
STK11 wild type N (% of cancers) |
| All patients | 4446 | 60/4446 (1.4%) | 4386/4446 (98.6%) |
| Lung non-small cell cancers | 384 | 27/384 (7%) | 357/383 (93%) |
| Head and neck cancers | 92 | 4/92 (4.4%) | 88/92 (95.6%) |
| Anal Squamous cell cancer | 17 | 3/17 (17.6%) | 14/17 (82.4%) |
| Pancreatic adenocarcinoma | 160 | 1/160 (0.6%) | 159//160 (99.4%) |
| Breast cancer | 379 | 4/379 (1.1%) | 375//379 (98.9%) |
| Cholangiocarcinoma | 106 | 3/106 (2.8%) | 103/106 (97.2%) |
| Appendiceal cancer | 123 | 3/123 (2.4%) | 120/123 (97.6%) |
| Colorectal cancer | 421 | 2/421 (0.5%) | 419/421 (99.5%) |
| Carcinoma unknown primary | 287 | 3/287 (1.4%) | 284/287 (98.6%) |
| Other*** | 2477 | 10/2477 (0.4%) | 2467/2477 (99.6%) |
**
Median time to progression refers to time from diagnosis to metastases or progression and is used in Table 1.
***
Other consists of hematologic malignancies (N = 348); prostate cancer (N = 209, brain tumors (N=272), gastrointestinal cancers (N= 396), melanoma and other skin cancers (N=221), thyroid cancers (N= 198), ovarian cancer (N= 236), endometrial and cervical cancers (N=148 includes 23 cervical cancers), sarcomas (N= 249)
Abbreviations: CI = confidence interval; ctDNA = circulating tumor DNA; NGS = next generation sequencing; NSCLC = non-small cell lung cancer; VUS = variant of unknown significance